Header Logo

Connection

Nirav Shah to Drug Resistance

Back to Details
This is a "connection" page, showing publications Nirav Shah has written about Drug Resistance.
Nirav Shah
Connection Strength
0.040
Drug Resistance
  1. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 05 14; 135(20):1739-1749.
    View in: PubMed
    Score: 0.040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.